A471820 Stock Overview

Focuses to merge with other companies. More details

A471820 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	1/6

Risk Analysis

Has not reported any financial data

Does not have a meaningful market cap (₩62B)

Cellromax Science Co., Ltd. Competitors

T.S. Investment

KOSDAQ:A246690

₩97.9b

Stonebridge Ventures

KOSDAQ:A330730

₩75.7b

SV Investment

KOSDAQ:A289080

₩82.3b

Lindeman Asia Investment

KOSDAQ:A277070

₩83.0b

Price History & Performance

Summary of share price highs, lows and changes for Cellromax Science
Historical stock prices
Current Share Price	₩5,290.00
52 Week High	₩8,840.00
52 Week Low	₩4,355.00
Beta	0
1 Month Change	6.12%
3 Month Change	2.32%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-33.54%

Recent updates

Shareholder Returns

	A471820	KR Capital Markets	KR Market
7D	15.0%	3.9%	2.2%
1Y	n/a	11.7%	-6.5%

Return vs Industry: Insufficient data to determine how A471820 performed against the KR Capital Markets industry.

Return vs Market: Insufficient data to determine how A471820 performed against the KR Market.

Price Volatility

Is A471820's price volatile compared to industry and market?
A471820 volatility
A471820 Average Weekly Movement	6.5%
Capital Markets Industry Average Movement	4.1%
Market Average Movement	6.2%
10% most volatile stocks in KR Market	12.6%
10% least volatile stocks in KR Market	2.9%

Stable Share Price: A471820 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: Insufficient data to determine A471820's volatility change over the past year.

Community vs My Fair Value

Select a narrative for quick price alerts from the community, or create your own.

About the Company

Founded	Employees	CEO	Website
2022	n/a	n/a	hanwha-plus-no3spac.com

Cellromax Science Co., Ltd. focuses to merge with other companies. The company was founded in 2022 and is based in Seoul, South Korea.

Cellromax Science Co., Ltd. Fundamentals Summary

How do Cellromax Science's earnings and revenue compare to its market cap?
A471820 fundamental statistics
Market cap	₩61.60b
Earnings (TTM)	₩0
Revenue (TTM)	n/a

n/a

P/E Ratio

n/a

P/S Ratio

Is A471820 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A471820 income statement (TTM)
Revenue	₩0
Cost of Revenue	₩0
Gross Profit	₩0
Other Expenses	₩0
Earnings	₩0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did A471820 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

n/a

Payout Ratio

Does A471820 pay a reliable dividends?

See A471820 dividend history and benchmarks

When do you need to buy A471820 by to receive an upcoming dividend?
Cellromax Science dividend dates
Ex Dividend Date	Dec 27 2024
Dividend Pay Date	Apr 22 2025
Days until Ex dividend	113 days
Days until Dividend pay date	3 days

Does A471820 pay a reliable dividends?

See A471820 dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/18 07:46
End of Day Share Price	2025/04/18 00:00
Earnings	N/A
Annual Earnings	N/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cellromax Science Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Cellromax Science KOSDAQ:A471820 Stock Report